MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Suletud

SektorTervishoid

2.68 -1.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.67

Max

2.73

Põhinäitajad

By Trading Economics

Sissetulek

-5.9M

247K

Müük

5.1M

62M

Kasumimarginaal

0.395

Töötajad

181

EBITDA

-6.1M

7.4M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+156.41% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-162M

726M

Eelmine avamishind

4.15

Eelmine sulgemishind

2.68

Uudiste sentiment

By Acuity

94%

6%

356 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Akebia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. sept 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30. sept 2025, 23:43 UTC

Kuumad aktsiad

Stocks to Watch: GEO Group, Lithium Americas, Nike

30. sept 2025, 23:12 UTC

Tulu

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30. sept 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30. sept 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Lifeway Foods, Danone Agree to Stay Litigation

30. sept 2025, 21:17 UTC

Tulu

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30. sept 2025, 20:47 UTC

Tulu

Nike 1Q Sales Rise as Turnaround Progresses

30. sept 2025, 23:45 UTC

Market Talk

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30. sept 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30. sept 2025, 23:26 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30. sept 2025, 23:26 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30. sept 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30. sept 2025, 23:24 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30. sept 2025, 23:24 UTC

Omandamised, ülevõtmised, äriostud

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30. sept 2025, 22:54 UTC

Market Talk

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30. sept 2025, 22:38 UTC

Tulu

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30. sept 2025, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. sept 2025, 22:32 UTC

Market Talk

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30. sept 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30. sept 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30. sept 2025, 21:02 UTC

Tulu

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30. sept 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. sept 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

30. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. sept 2025, 20:28 UTC

Tulu

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30. sept 2025, 20:22 UTC

Tulu

Nike 1Q North America Revenue $5.02B >NKE

30. sept 2025, 20:22 UTC

Tulu

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30. sept 2025, 20:22 UTC

Tulu

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30. sept 2025, 20:22 UTC

Tulu

Nike 1Q Greater China Revenue $1.51B >NKE

30. sept 2025, 20:19 UTC

Tulu

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Võrdlus sarnastega

Hinnamuutus

Akebia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

156.41% tõus

12 kuu keskmine prognoos

Keskmine 7 USD  156.41%

Kõrge 8 USD

Madal 6 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Akebia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.345 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

356 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat